Scientists reported discovery of potent cross‑neutralizing human antibodies that neutralize Marburg virus and the related Ravn virus, according to a paper in npj Viruses. The antibodies target conserved glycoprotein epitopes and showed broad neutralization in in vitro assays, suggesting potential for therapeutic monoclonals or templates for vaccine immunogen design. The team characterized binding sites and neutralization breadth, providing preclinical candidates for further development. The study’s mechanistic insights could accelerate countermeasure pipelines against high‑consequence filoviruses.